---
schema_version: "secwatch.filing_event.v1"
accession: "0001770787-23-000051"
form_type: "8-K"
ticker: "TXG"
cik: "0001770787"
company_name: "10x Genomics, Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:43:31.270044+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# 10x Genomics Q3 revenue $153.6M (+17% YoY), net loss $93.0M; raises FY2023 guidance

## Summary
- Q3 2023 revenue $153.6M, up 17% YoY; raised FY2023 guidance to $610-625M.
- Gross margin fell to 62% from 77% YoY due to product mix from Xenium instrument placements.
- Operating loss $94.8M ($40.0M prior year); includes $41.4M in-process R&D and $40.2M stock comp.
- Net loss $93.0M vs $41.9M; cash & securities $356.9M as of Sep 30.
- Xenium platform driving demand; launched new panel configurations and Beckman Coulter partnership.

## SEC filing metadata
- accession: 0001770787-23-000051
- form_type: 8-K
- ticker: TXG
- cik: 0001770787
- company_name: 10x Genomics, Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770787/000177078723000051/0001770787-23-000051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770787/000177078723000051/txg-20231102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001770787-23-000051
- JSON: https://secwatch.observer/filing/0001770787-23-000051.json
- Plain text: https://secwatch.observer/filing/0001770787-23-000051.txt

## Key facts
- Earnings Releases
  10x Genomics, Inc. reported for the third quarter ended September 30, 2023 results: revenue $153.6 million, net income Net loss was $93.0 million. Guidance raised.
  - Period: for the third quarter ended September 30, 2023
  - Revenue: $153.6 million
  - Net income: Net loss was $93.0 million
  - Guidance: raised
  - Result: reported results
  source text: Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights • Revenue was $153.6 million for the third quarter, a 17% increase over the corresponding period of 2022, driven by Xenium momentum. • Advanced Xenium gene panel strategy, launching new targeted and custom
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770787/000177078723000051/0001770787-23-000051-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.